[Tetrahydrobiopterin therapy for hyperphenylalaninemia due to phenylalanine hydroxylase deficiency. When and how?]

An Pediatr (Barc). 2006 Feb;64(2):146-52. doi: 10.1157/13084174.
[Article in Spanish]

Abstract

Introduction: Some patients with hyperphenylalaninemia due to phenylalanine hydroxylase deficiency respond with a variable decrease in plasma phenylalanine levels after oral tetrahydrobiopterin (BH4) administration and are then able to tolerate higher dietary phenylalanine intake or even to discontinue a phenylalanine-restricted diet. BH4-sensitive patients are usually identified by means of a BH4 loading test, but consensus on the methodology of this test and the interpretation of its results is lacking. Consequently, a simple tool to identify which patients are likely candidates for this treatment and how they will progress in the long-term is required.

Material and methods: A combined oral BH4 loading test with phenylalanine (100 mg/kg) and BH4 (20 mg/kg) was performed in 20 patients with hyperphenylalaninemia under dietary phenylalanine restriction.

Results: Independently of the genotype, the result was positive in all the 9 patients whose maximum phenylalanine level at diagnosis was below 815 nmol/ml. Currently, they are under treatment with tetrahydrobiopterin doses of 7-15 mg/kg/day. All these patients have been able to increase their oral phenylalanine intake. Six are currently following a normal diet and the remaining three are close to reaching this goal. None of the patients with a maximum phenylalanine level at diagnosis higher than 938 nmol/ml responded to the BH4 loading test.

Conclusions: The maximum phenylalanine level at diagnosis seems to be a simple and reliable method to predict response to BH4 treatment. A high percentage of BH4-sensitive patients are able to discontinue a phenylalanine-restricted diet after long-term tetrahydrobiopterin treatment.

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Biopterins / administration & dosage
  • Biopterins / analogs & derivatives*
  • Biopterins / metabolism
  • Biopterins / therapeutic use
  • Child
  • Child, Preschool
  • Genotype
  • Humans
  • Infant
  • Infant, Newborn
  • Nitric Oxide Synthase / metabolism
  • Phenylalanine Hydroxylase / deficiency*
  • Phenylalanine Hydroxylase / genetics
  • Phenylketonurias / drug therapy*
  • Phenylketonurias / genetics
  • Phenylketonurias / metabolism

Substances

  • Biopterins
  • Nitric Oxide Synthase
  • Phenylalanine Hydroxylase
  • sapropterin